ReviewCurrent opinion in HIV and AIDS2010
Biomarkers and HIV-associated cardiovascular disease.
Review in Current opinion in HIV and AIDS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Effects and safety of Chinese herbal medicine on inflammatory biomarkers in cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2022Pooled it
- Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate.Arteriosclerosis, thrombosis, and vascular biology · 2018Trial
- Thromboinflammatory biomarkers and thrombotic risk in virologic failure and drug-resistant HIV: Emerging roles of d-dimer, fibrinogen, and coagulation dysregulation.Journal of thrombosis and thrombolysis · 2026Review
- Developing machine learning models to improve cardiovascular risk prediction for people living with HIV.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Article
- Mediterranean diet adherence and systemic inflammation in people with HIV and PrEP users.Frontiers in nutrition · 2026Article
- Validity of high-sensitivity C-reactive protein versus DAD equation for cardiovascular risk assessment in people living with HIV in Nigeria.BMC infectious diseases · 2025Article
- Predictive Model for the Detection of Subclinical Atherosclerosis in HIV Patients on Antiretroviral Treatment.Current HIV research · 2025Observational
- Maternal biomarkers of endothelial dysfunction and pregnancy outcomes in women with and without HIV in Botswana.PloS one · 2023Article
- Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection.PLoS biology · 2021Article
- Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations.Current HIV/AIDS reports · 2021Review
- Extracellular Vesicle-Related Thrombosis in Viral Infection.International journal of general medicine · 2020Review
- Effects of HIV-1 gp120 and TAT-derived microvesicles on endothelial cell function.Journal of applied physiology (Bethesda, Md. : 1985) · 2019Article
- Plasma glycomics predict cardiovascular disease in patients with ART-controlled HIV infections.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Article
- Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy.The Journal of infectious diseases · 2018Article
- Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children.AIDS (London, England) · 2018Article
- Triad of the Ischemic Cardiovascular Disease in People Living with HIV? Association Between Risk Factors, HIV Infection, and Use of Antiretroviral Therapy.Current atherosclerosis reports · 2018Review
- Article
- Stimulation of PBMC and Monocyte-Derived MacrophagesFrontiers in immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewOur goal is to summarize recent literature on biomarkers of cardiovascular disease (CVD) in the setting of HIV infection with an emphasis on those associated with clinical events. RECENT
findingsEpidemiological data have demonstrated that HIV infection is associated with increases in well established markers of inflammation and thrombosis, and levels of high sensitivity C-reactive protein, interleukin-6, and D-dimer predict CVD and mortality risk in HIV cohorts. Levels of interleukin-6, D-dimer and endothelial adhesion molecules increase when antiretroviral therapy is interrupted, suggesting that HIV replication may be driving CVD risk in this context. However, data on changes in many CVD biomarkers after starting antiretroviral therapy are inconsistent or lacking. Finally, high-density lipoprotein particles may be more informative than other lipoprotein measures for CVD risk specifically among individuals with HIV infection. SUMMARY: Biomarkers of inflammation and thrombosis have the potential to improve CVD risk stratification beyond traditional and HIV-specific factors, and may prove useful for evaluating CVD prevention strategies for individuals with HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.